Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

Patients with chronic kidney disease (CKD) have a high risk of hyperkalemia, which increases mortality and can lead to renin–angiotensin–aldosterone system inhibitor (RAASi) dose reduction or discontinuation. Patiromer, a nonabsorbed potassium binder, has been shown to normalize serum potassium in p...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Kidney Int
Main Authors: Bushinsky, David A, Williams, Gordon H, Pitt, Bertram, Weir, Matthew R, Freeman, Mason W, Garza, Dahlia, Stasiv, Yuri, Li, Elizabeth, Berman, Lance, Bakris, George L
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2015
Assuntos:
Clinical Trial
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4678168/
https://ncbi.nlm.nih.gov/pubmed/26376130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ki.2015.270
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares